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BCL11B REGULATES ARTERIAL STIFFNESS BY REGULATING VASCULAR 
SMOOTH MUSCLE CONTRACTILITY 
 
PAVANIA ELAVALAKANAR 
ABSTRACT 
Background: Arterial stiffness (AS), or loss of elastic compliance of large arteries, is an 
independent risk factor for cardiovascular events1. A recent study demonstrated that single 
nucleotide polymorphisms (SNPs) in a genetic locus downstream of the gene Bcl11b are 
associated with AS2. However, how this genetic locus and Bcl11b regulate AS is unknown.  
Objectives: To determine the molecular mechanisms by which Bcl11b effects the aortic 
wall and AS.  
Methods: Vascular smooth muscle (VSM) cells were isolated from aortas of wildtype 
(WT) mice and mice with VSM-specific Bcl11b deletion (BKO). mRNA levels of Bcl11b, 
vascular contractile markers (myosin heavy chain 11 (MYH11), smooth muscle -actin 
(ACTA2), and myocardin (MYOCD)) and a cell proliferation marker (Ki67) were 
measured in WT and BKO VSM cells isolated from murine aortas. VSM cell contractility 
in response to angiotensin II (angII), a contractile stimulus, was measured in WT and BKO 
VSM cells using an optimized collagen gel contractility assay. 
Results: BKO VSM cells had decreased expression of contractile markers compared to 
WT cells, which resulted in impaired collagen gel contraction in response to angII.  
Conclusions:  Bc111b is expressed in aortic smooth muscle cells and it regulates the 
expression of VSM contractile proteins. Our data strongly supports the hypothesis that 
Bcl11b regulates AS by regulating the contractile function of VSM cells in the aortic wall.   
 vi 
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INTRODUCTION 
 
 Cardiovascular diseases (CVDs) are the leading cause of death in the United States 
of America (USA)3. CVDs develop due to a variety of risk factors including age, obesity 
and hypertension, which may lead to stroke and heart failure4–7. Recently, arterial stiffness 
(AS), a vascular condition characterized by the loss of elastic compliance in large arteries, 
has emerged as an independent risk factor for CVDs1. AS increases significantly in 
overweight or aging individuals, increasing their risk of developing CVDs8,9.  Considering 
that factors of obesity and being overweight reached epidemic proportions in the US (68% 
of Americans are overweight/obese), the number of people susceptible to CVDs also 
increases10. However, our understanding of the cellular and molecular mechanisms of AS 
remains limited, hampering the discovery of therapeutic targets to prevent or ameliorate 
AS.  The goal of our laboratory is to determine the cellular and molecular pathways 
underlying AS. 
 
Arterial Stiffness 
 A recent epidemiological study examined AS in the general population over 8 
years. Individuals with the highest baseline pulse wave velocity (PWV > 11.8 m/s), the 
gold standard clinical measure of AS, developed a significantly higher number of 
cardiovascular events compared to individuals with lower baseline PWV (< 11.7 m/s) 
(Figure 1)1. These results highlight the role AS plays in progressing CVDs and establishes 
AS as an independent predictor of CVDs1. 
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Figure 1: Correlation between arterial stiffness and increased cardiovascular events. 
Individuals with the highest baseline pulse wave velocity (PWV) (black) showed an 
increase in cardiovascular events over 8 years compared to groups with a lower baseline 
PWV (grey, off-white, white)1 (Adapted from Mitchell et al., Circulation, 2010).  
 
Arterial stiffness is a vascular disease resulting in the loss of elastic compliance of 
large vessels and may contribute to CVDs by multiple mechanisms. Large elastic arteries 
have a characteristic known as arterial compliance, which is the ability of the vessel wall 
to expand in response to cardiac contraction and to recoil during diastole (Figure 2)11. In 
contrast, small muscular vessels function mainly in the distribution of blood flow within 
tissues and organs12 and in the regulation of blood pressure.  
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Figure 2: Effect of arterial stiffness on blood flow propagation. (Left) In elastic arteries 
there is a buffering of systolic/pulse pressure after cardiac contraction and diastolic flow is 
sustained by aortic wall recoil (Windkessel effect). (Right) In stiff arteries, systolic 
pressure increases and diastolic flow decreases11 because of loss of arterial compliance 
(Adapted from Briet et al., Kidney International, 2012). 
 
Pulse wave velocity (PWV), the gold standard in vivo measure of arterial 
stiffness13,14, measures the speed of blood pressure wave propagation along the aorta after 
cardiac contraction. Importantly, aortic but not peripheral PWV increases as we age, 
indicating that large elastic arteries as opposed to smaller resistive vessels stiffen with 
aging (Figure 3)1.  As the aortic wall stiffens, mainly with aging or obesity, the velocity of 
blood pressure wave propagation increases due to the loss of aortic compliance, which 
results in increased PWV. 
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Figure 3: PWV in the aging population. As age increases, PWV, the in vivo index of AS, 
increases in large elastic vessels, such as the aorta (red), but remains relatively constant in 
smaller resistive peripheral vessels (green)1 (Adapted from Mitchell et al., Circulation, 
2010).  
  
When large arteries are elastic under normal vascular conditions, the forward blood 
flow wave coming from the heart encounters the blood flow in smaller muscular arteries 
as it travels along the arterial tree, resulting in an optimal timing of wave reflection. That 
is, aggregations of these reflected waves with the forward propagating wave results in an 
anterograde wave returning to the heart during diastole, which ensures an adequate 
coronary diastolic perfusion12,15.   
In contrast, as the aortic wall stiffens, the cardiac output flows down the arterial 
tree more rapidly as PWV increases. Subsequently, as both the forward and reflected waves 
travel faster, the reflected wave collides with the forward wave earlier, i.e. during systole12. 
As a result, systolic pressure drastically increases, cardiac afterload increases and diastolic 
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coronary perfusion decreases12,16, overall impairing cardiac function. In addition, increased 
systolic and pulse pressures due to stiff arteries, may damage the microcirculation in 
downstream organs particularly in high flow/low resistance organs such as the brain and 
kidneys, which are more prone to microvascular damage17.  
Lastly, as forward blood flow during diastole decreases because of the lack of 
elastic recoil, there may be an impairment of proper blood supply to peripheral organs. As 
a consequence, there is an improper exchange of wastes and nutrients between the blood 
and tissues11.  Therefore, AS results in dire effects on the heart and downstream organs by 
multiple mechanisms, ultimately leading to an increased risk of cardiovascular 
complications.   
 
Models of Arterial Stiffness 
 Aging and obesity are established models of AS. Aging affects several aspects of 
the cardiovascular system, with AS being a prominent result. Age-related stiffening of the 
vasculature occurs primarily through the decrease in elastic properties of the vessels due to 
an imbalance between collagen and elastin as a result of ECM remodeling7,18. As people 
age, there is increased thinning and degeneration of the elastic laminae in the tunic media 
of large vessels, possibly due to age-related material fatigue and fracture19,20. 
Consequently, there is increased mechanical load placed on the stiffer collagen fibers. In 
addition to elastin fragmentation, there is an increase in the deposition of collagen with 
age, especially after the age of 50 years21,22. In a study examining the effects of aging on 
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AS, measurements of PWV increased exponentially with each decade after 50-60 years of 
age (Figure 4)23. 
 
Figure 4: Link between aging and arterial stiffness. Age of individuals is represented 
along the X-axis. As aging increases, there is a drastic increase in PWV in both men and 
women23 (Adapted from AlGhatrif et al., Hypertension, 2013). 
 
 Recent studies from our laboratory demonstrated that AS develops rapidly in a 
murine model of dietary obesity. Mice fed a high-fat, high-sucrose (HFHS) diet, mimicking 
human obesity8, had increased  PWV within one month in comparison to mice fed a normal 
diet (ND)8 (Figure 5). Interestingly, systolic blood pressure increased after 6 months of 
HFHS, indicating that not only does AS develop with obesity but it precedes the 
development of hypertension8. Remarkably, upon reversal of mice from HFHS  to  ND, 
which resulted in significant weight loss, PWV decreased alongside a decrease in systolic 
blood pressure, indicating that the reversal of obesity can play a role in ameliorating both 
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macro- and micro-vascular damages associated with obesity8. These results suggest that 
obesity and associated metabolic impairment can lead to a rapid development of AS 
thereby increasing the risk of CVD in obese individuals, who can become more prone to 
myocardial infarction, cardiac dysfunction, and hypertension1.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: PWV measurements in obese and normal diet-fed mice. Mice fed a HFHS 
diet had increased PWV compared to mice fed a ND8. (Reproduced from Weisbrod et al. 
Hypertension, 2013) 
 
Pathophysiology of Arterial Stiffness 
 The normal aortic wall is composed of three layers: tunica intima, tunica media, 
and tunica adventitia. The tunica intima is composed of a layer of endothelial cells, facing 
the lumen of the vessel. The middle tunica media layer is comprised of alternating layers 
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of VSMCs and fenestrated elastic sheets, and contains fibrillar collagen. It is the tunica 
media layer that is mainly responsible for the compliance of the aorta and gives the vessel 
the ability to contract and dilate18. The outermost layer of the aorta, the tunica adventitia, 
is primarily composed of fibroblasts. This layer provides further mechanical support to the 
artery and contains smaller vessels, called vasa vasorum, which supply the aortic wall with 
nutrients.  
One of the most common mechanisms mediating AS involves an imbalance in 
extracellular matrix (ECM) remodeling of the aortic wall. Compliance of the arterial wall 
is dependent mainly on elastin, whose amount is genetically established from birth, and 
dynamic processes of formation and degradation of collagen24, thereby affecting the ECM 
composition of the vessel wall. Increased inflammation in the settings of diabetes, obesity, 
aging or other conditions, may stimulate overproduction of collagen, a substance that 
confers tensile strength to the vessel thereby stiffening the arterial wall. In addition, 
increased fragmentation of elastin may occur in response to inflammation, resulting in a 
loss of the elasticity of the vessel24. Moreover, factors such as excess glucose in diabetic 
individuals can result in post-translational modifications and improper covalent cross-
linking of collagen fibers greatly affecting the mechanical properties of the aortic wall and 
contributing to AS25. Under normal conditions matrix metalloproteinases, ECM-degrading 
enzymes, regulate aortic modelling, however an upregulation of the metalloproteinases can 
also weaken the ECM via enzymatic degradation of cross-links between collagen and 
elastin26. Deposition of other ECM components, such as glycoproteins, proteoglycans, and 
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increased medial and intimal calcifications leads to the thickening of the vessel wall ECM 
and as a result can also contribute to increased AS18,24.  
In addition to the established role of ECM in regulating arterial wall stiffness, a 
recent study observed that an increase in VSMC stiffness correlated with an increase in 
AS27. This study determined that under normal conditions the stiffness of VSMCs is a 
dynamic process mainly dependent on cellular cytoskeletal components. However, during 
aging, a change in the expression of cellular cytoskeletal components in VSMCs brings 
about an increase in AS27. VSMCs normally form adhesive connections with the ECM via 
integrins forming focal adhesion plaques that help mediate cell-to-cell junctions27. 
Saphirstein et al. observed that focal adhesion connecting the cytoskeleton of VSMCs to 
the ECM were impaired in aged aortas mainly due to downregulation of FAK-Src 
signaling, resulting in increased AS28,29. Subsequently, not only does VSMC stiffness 
affect AS, but alterations in the mechanisms regulating the remodeling of molecular 
contractile markers and cytoskeletal processes27 also significantly affect AS.  
In addition to ECM remodeling and alterations in VSMC stiffness, other 
mechanisms contributing to vascular stiffness, include abnormal vascular smooth muscle 
tone which has been linked to the suppression of nitric oxide (NO) production. NO 
regulates VSMC tone by acting as a vasodilator released by the endothelial cells of the 
vessel. During conditions of excessive oxidant stress, which leads to abnormal superoxide 
and other free radical production, superoxide can rapidly react with NO to form highly 
reactive oxygen and nitrogen species which in turn promote abnormal vascular tone18. In 
addition, certain hormones such as angiotensin II, induce AS by stimulating collagen 
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production, dynamic ECM remodeling, vascular hypertrophy, depression of nitric oxide 
signaling, and downregulation of elastin synthesis24. However, specific genetic and 
molecular mechanisms contributing to AS have not been delineated.   
 
Bcl11b: A potential regulator of arterial stiffness 
A recent genome-wide association study demonstrated for the first time that single 
nucleotide polymorphisms (SNPs) in a genomic region on chromosome 14 is highly 
correlated with increased AS2. Interestingly, a 500 bp (base pair) region within this genetic 
locus has 98% homology between human and mice2, suggesting that this highly conserved 
region may bare important biological functions. A detailed analysis revealed the presence 
of a long non-coding ribonucleic acid (lncRNA), DB129663, overlapping a region known 
to function as an enhancer for the gene B-cell lymphoma/leukemia 11B (Bcl11b)2, which 
is located downstream of this locus.   
Bcl11b is a zinc finger transcription factor expressed in all T-cell subsets30, where 
it is necessary for T-cell commitment at the double negative 2 stage, a crucial step for T-
cell development, and for positive selection of CD4+ and CD8+ thymocytes30. Bcl11b is 
also important in the survival of mature neurons and the functioning of new neurons31. An 
impairment in Bcl11b expression in selected brain areas, such as the hippocampus, results 
in impaired spatial working memory, highlighting its importance in neurogenesis32. 
However, whether Bcl11b has other biological functions in addition to the well-established 
roles in neurons and the immune system, is unknown.  
 11 
 Based on the human genomic study demonstrating an association between the 
Bcl11b genetic locus and increased PWV, our laboratory sought to determine whether 
Bcl11b may play a role in vascular function. We conducted preliminary experiments 
measuring PWV in WT and global Bcl11b knock out (BKO) mice. We found that PWV 
was increased in BKO mice compared to WT controls, over a wide range of mean arterial 
pressures (Figure 6).  
 
 
 
 
 
 
 
 
 
Figure 6: PWV assessed in WT mice and BKO mice. PWV was measured invasively 
using pressure transducers. BKO mice (red) have increased PWV compared to WT mice 
(black). The square indicates physiological range of mean arterial pressure in mice (90-110 
mmHg). 
 
However, these findings raised the question of which cell type expressing Bcl11b (T-cells, 
neurons or other) may be responsible for Bcl11b regulation of AS. Therefore, we examined 
whether the aorta itself may be a possible location of Bcl11b expression by using a reporter 
mouse in which a fluorescent protein (mTomato) is expressed after removal of Bcl11b. 
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Examination of aortic sections using immunofluorescence microscopy, clearly 
indicated the presence of Bcl11b in the aorta (Figure 7A). mRNA measurements by qRT-
PCR and protein analysis by Western blotting, further confirmed Bcl11b expression in the 
aorta (Figure 7B).  
 
 
Figure 7: Bcl11b detected in mouse aorta. (A) Fluorescent mTomato knock-in indicates 
that Bcl11b is expressed in the vascular smooth muscle. (B) Bcl11b mRNA (graph) and 
protein levels (insert) detected in mouse aortic samples indicate that Bcl11b is expressed 
at levels comparable to the brain and thymus, two organs known to express Bcl11b at high 
levels. 
 
These results were crucial in demonstrating for the first time that Bcl11b is present within 
the vasculature and may be responsible for the AS observed in whole body BKO mice 
(Figure 6).  
We further established a link between Bcl11b and AS using two established models 
of AS: aged and obese mice. In both aged (29-months old) and HFHS-fed mice, Bcl11b 
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mRNA levels were significantly decreased in comparison to young mice and normal diet 
(ND)-fed mice, respectively (Figure 8), further highlighting a correlation between Bcl11b 
and AS. However, the mechanisms by which Bcl11b regulates vascular smooth muscle cell 
function and AS are unknown.  
 
 
 
 
Figure 8: mRNA levels of Bcl11b in two models of arterial stiffness. (Left) Bcl11b 
mRNA levels in young vs. 29-month old mice. Bcl11b mRNA is significantly decreased 
in aged mice. (Right) Bcl11b mRNA levels in mice fed normal diet (ND) vs. mice fed high-
fat high-sucrose diet (HFHS). Bcl11b mRNA is significantly decreased in obese mice. 
 
Therapeutic Interventions and Future Implications 
 Early nonpharmacological and pharmacological intervention and treatment of 
vascular stiffness can help reduce the occurrence of cardiovascular events. Previously 
examined nonpharmacological interventions include lifestyle modifications such as 
aerobic exercise training and dietary modifications4. Some pharmacological interventions 
may include angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor 
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blockers, and antibodies against the inflammatory cytokine TNF-α, although the efficacy 
of these medications to directly decrease AS are still being investigated4.   
 By uncovering a role of Bcl11b in regulating vascular stiffness, pharmacological 
agents may be designed to target the Bcl11b gene region to possibly modulate the 
progression of vascular stiffness.  
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SPECIFIC AIMS 
 The goal of this study was to examine the role of Bcl11b in AS and vascular smooth 
muscle cells. A previous study indicated a correlation between SNPs in the genetic region 
downstream of Bcl11b and AS, yet the role of Bcl11b and its downstream targets in 
regulating AS have not been examined. The region containing SNP variants highly 
associated with AS corresponds to the lncRNA DB129963, which overlaps with a Bcl11b 
enhancer. We hypothesize that this region downstream of Bcl11b, containing DB129663 
and the Bcl1b enhancer, regulates Bcl11b gene transcription. In turn, Bcl11b regulates 
downstream mechanisms, which we hypothesize are important for normal vascular smooth 
muscle function (Figure 
9). The presence of 
SNPs in the region 
downstream of Bcl11b 
may impair the 
regulatory apparatus of 
Bcl11b, which may 
result in VSM 
dysfunction and 
increased AS. The 
present study examined the molecular mechanisms downstream of Bcl11b in VSMCs and 
how these Bcl11b-dependent mechanisms relate to VSM function and the development of 
AS.    
Figure 9: Working hypothesis – SNPs (red stars) in an 
enhancer region downstream of Bcl11b can result in a 
dysregulation of Bcl11b which leads to an increase in arterial 
stiffness. 
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MATERIALS AND METHODS  
Animal Studies 
 Mice with a floxed Bcl11b gene were bred with mice expressing Cre-recombinase 
under the promoter of myosin heavy chain 11 (MYH11), a vascular smooth muscle specific 
gene, to generate mice with VSM-specific Bcl11b deletion (BKO). To note, Cre-
recombinase is fused to an estrogen receptor, therefore Cre-recombinase expression in 
VSM cells occurs only after administration of the estrogen receptor agonist tamoxifen. 
Mice were injected for five consecutive days with tamoxifen (2 mg/day). Activation of 
Cre-recombinase after tamoxifen administration allows Bcl11b to be excised at the floxed 
Bcl11b site to generate BKO mice, while WT controls were generated by administering 
vehicle (oil) for five consecutive days.  
 
Mice Genotyping 
 To determine the genotype of experimental mice, tails were snipped and digested 
using a digestion buffer (1.5M Tris-HCl, pH 8.8; 1M (NH4)2SO4, 1M MgCl2, 100% Triton 
X-100, H2O), containing proteinase K and β-mercaptoethanol (14.3M). Tails were 
incubated in digestion buffer at 58o C overnight to extract genomic DNA. Samples were 
then placed on a 96o C heat block for 8 mins to inactivate proteinase K, and cleared of tail 
debris by centrifugation. 1 uL of extracted DNA solution was then used in a polymerase 
chain reaction (PCR) using Bcl11b gene specific primers (PCR cycling conditions: 
denaturation 94oC for 40 s, annealing 56oC for 40 s, extension 72oC for 40 s, n=35 cycles). 
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PCR products were run on 1.5% agarose gels using electrophoresis in the presence of a 
nucleic acid staining dye (GelRed Nucleic Acid – 10,000X in DMSO). The resulting bands 
were visualized under ultraviolet (UV) light using the Step Quantity One software. A 
predicted band size of 350 bp is indicative of floxed Bcl11b mouse genotype (Figure 10, 
top panel), a 250 bp band is indicative of WT (Figure 10, top panel), and a 450 bp band is 
indicative of VSM Bcl11b deletion, after tamoxifen administration (Figure 10, bottom 
panel).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Mouse genotype. (Top) Band size of ~345 bp corresponds to a floxed Bcl11b 
(fl/fl) genotype. Band size of ~250 bp is indicative of WT.  (Bottom) A ~450 bp band 
indicates Bcl11b deletion after tamoxifen-induced Cre recombinase in VSM cells (del). 
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Vascular Smooth Muscle Cells Isolation and Culture 
 Aortas from WT and BKO mice were carefully dissected by removing fat and 
connective tissue. Isolated aortas were incubated in 3 mg/mL collagenase at 37o C for 
15mins. The aortas were manually stripped of their adventitia (the outer layer of the aorta) 
to avoid the inclusion of adventitial fibroblasts in the VSM cell preparation. VSMCs were 
obtained by further enzymatic digestion of VSM with 3 mg/mL collagenase and 1mg/mL 
elastase at 37o C for 45 mins. The cell suspension was centrifuged at 1200 rpm at 4o C for 
5 mins, and cells were washed and re-suspended in cold phosphate-buffered saline (PBS). 
Cells were then centrifuged at 1200 rpm at 4oC for 5 mins and re-suspended in culture 
DMEM medium containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic 
(AA). This culture medium provides optimal conditions for VSMC growth and 
proliferation but not for endothelial cells, which do not survive and are discarded. VSM 
cells were seeded on collagen-coated plates and incubated at 37o C in 2 mL culture medium. 
Medium was replaced with fresh medium every 48 hours. After primary cell growth for 7-
10 days in collagen-coated plates, cells were collected using 0.25% trypsin and re-seeded 
on larger 10 cm plastic petri dishes in 6 mL of medium. Cells at passages 2-4 were used 
for experiments. 
 
RNA Extraction, Isolation, and Reverse Transcription to cDNA 
 In a subset of experiments, VSMCs were starved for 72 hours in DMEM without 
FBS, while control plates remained in DMEM-10% FBS. Cells were washed in PBS and 
detached using 1 mL 0.25% trypsin at 37o C for 5 mins. The detached cells were neutralized 
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in 4 mL DMEM-10% FBS and centrifuged at 1000 rpm for 8 mins at 4oC. The pellet was 
re-suspended, washed in 5 mL PBS and re-centrifuged. The entire work station was sprayed 
with RNase away to protect samples from RNA degradation. PBS was aspirated and 400 
uL of Trizol was added to lyse the cell pellet and extract RNA. The Trizol solution was run 
through RNA isolation columns using the Direct-Zol Zymogen kit, as per manufacturer’s 
instructions. The RNA was eluted from columns in 40-80uL of RNase-free water. 
Extracted RNA was used to generate complementary DNA (cDNA) with a High capacity 
RNA-to-cDNA kit from Applied Biosystems, as per manufacturer’s instructions. 
  
 Aorta Homogenizations 
 Isolated aortas were snap frozen in liquid nitrogen and kept at -80o C until further 
processing.  Frozen aortas were pulverized using liquid nitrogen and a mortar and pestle. 
The fine powder was immediately transferred into a glass-glass homogenator containing 
400 uL of Trizol. The powdered aorta was mechanically homogenized until the aorta 
appeared to be completely dissolved.  
 
RNA Extractions of Aortic Samples 
 Aortic samples digested in Trizol were mixed with 400 uL chloroform. The solution 
was gently vortexed and placed at room temperature for a few minutes before being 
centrifuged at 13,200 rpm for 10 mins at 4o C. The top clear aqueous layer of the 
centrifuged samples, containing RNA, was carefully transferred into clean eppendorf tubes 
and 500 uL isopropanol was added to precipitate the RNA. 1 uL glycogen was added for 
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visualization of the RNA pellet. Samples were centrifuged at 13,200 rpm for 10 mins at 
4oC. Supernatant was discarded and pellet washed in 1 mL of 70% ethanol. The samples 
were then centrifuged at 7500 rcf for 5 mins at room temperature. The ethanol was removed 
and the pellet re-suspended in 20 uL DEPC-treated RNase free water. The resulting RNA 
solution was then cleared of possible contaminating DNA by treatment with DNase 
(Ambion Turbo kit) for 30 mins at room temperature, after which DNase was inactivated, 
as per manufacturer’s instructions. Samples were centrifuged and RNA-containing 
supernatant was transferred to a new tube. Concentration and quality of extracted RNA 
were measured with a spectrophotometer (Nanodrop).  
 
Quantitative RT-PCR (qRT-PCR). 
 Bcl11b mRNA levels were measured on cDNA prepared from WT and BKO 
VSMCs cultured in medium containing 10% FBS or no FBS using quantitative RT-PCR 
with Thermofisher Scientific validated Taqman primers or custom-made Exiqon 
SYBRGreen primers. Similarly, Bcl11b mRNA was measured in RNA isolated from aortas 
of obese or aged mice and controls (ND-fed or young mice). qRT-PCR was also used to 
measure mRNA levels of VSM contractile proteins myosin heavy chain 11 (MYH11), 
smooth muscle -actin (ACTA2), and myocardin (MYOCD), and collagen 3 (Col3) and a 
cell proliferation marker Ki67. Beta-actin was used as an endogenous control and relative 
mRNA quantitation was calculated computationally using comparative delta-delta 
threshold (Ct) method and expressed relative to control.  
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Collagen Gel Contraction Assay 
 VSM cell contractility in response to angiotensin II, a contractile stimulus, was 
measured in WT or Bcl11b-deleted VSMCs, cultured with or without FBS, with a collagen 
gel contraction assay. Collagen gels (500 uL) were prepared in a 24-well plate by mixing 
400 uL 2.5x106/mL cell suspension with 200 uL of 3 mg/mL collagen solution. The 
collagen solution consisted of PBS, sodium hydroxide (NaOH), collagen and sterile-
filtered water. The cell-collagen mixtures were set at room temperature to polymerize for 
30 mins. The gels were then detached from the walls of the plate using a pipette tip. An 
additional 500 uL DMEM medium containing either angII (100 nM) or vehicle control was 
added and the gels were incubated at 37o C overnight. Digital pictures of the gels were 
taken at baseline and after 21 hours using the cellLens software under a dissecting 
microscope. The gel surface areas were manually measured using ImageJ software and gel 
contraction was calculated as a ratio between the gel surface area at baseline (time 0) and 
the surface areas after 21 hours angII. 
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RESULTS 
 
Vascular smooth muscle alterations in aortas of obese mice 
 In order to examine the vascular changes occurring in obesity-induced AS, previous 
work from the laboratory examined aortas of mice fed ND or HFHS diet. As shown in the 
introduction, obese mice had lower levels of Bcl11b mRNA (Figure 8) and protein 
expression (not shown) in comparison to ND-fed mice. Further examination revealed a 
significant  2-fold decrease in MYH11 in mice fed HFHS vs mice fed ND for 4 months 
(Figure 11A), suggesting a correlation between Bcl11b and MYH11 expression regulation. 
In addition, mice fed with HFHS-diet had a significantly thicker tunica media than 
ND-fed mice (Figure 11B) and an increased expression of inflammatory markers TNF-α 
and VCAM1, as detected by immunohistochemistry (Figure 11C; pink color indicates 
TNF-α and VCAM1 in the aortic sections). To determine whether these inflammatory 
markers were expressed within VSM cells rather than in immune cells, which may have 
infiltrated the aortic wall, VSM cells were isolated from aortas of obese and control mice 
and analyzed by Western blot. Statistically significant increases in TNF-α and VCAM1 
protein expressions were detected in VSMCs of HFHS-fed mice in comparison to ND-fed 
mice (Figure 11D), with TNF-α increasing by 2-fold and VCAM1 increasing by up to 4-
fold. Overall, these data suggest that in obesity-induced AS, aortas develop phenotypic 
alterations in VSM cells, as indicated by decreased contractile protein MYH11, increased 
proliferation (increased media thickness) and increased inflammatory markers, which are 
normally absent in healthy aortas. 
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Figure 11: VSM alterations in aortas of obese mice. A) mRNA levels of MYH11 were 
reduced in aortas of obese mice compared to normal mice B) Aortic thickness (mm2) was 
measured in aortic sections of ND and HFHS-fed mice. A significant increase in thickness 
was measured in the media of HFHS mice. C) Increased expression of inflammatory 
molecules TNF-alpha and VCAM1 in aortas of obese mice compared to ND-fed mice, as 
indicated by pink colored immunostaining. D) Protein expression of inflammatory markers 
(TNF, VCAM1 and phosphorylated NFkB) increased in VSM cells from aortas of obese 
mice compared to normal nice. 
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Bcl11b mRNA expression parallels VSM contractile markers expression 
 Based on these previous findings, my work sought to determine whether there was 
a correlation between Bcl11b and VSM phenotypic alterations associated with AS. Bcl1b 
and contractile markers (MYH11, ACTA2, and MYOCD) mRNA expressions were 
measured in homogenized aortas and vascular smooth muscle cells. mRNA levels of 
contractile markers were significantly decreased in cultured VSMCs compared to the aorta 
(Figure 13), as expected considering that cultured VSMCs in vitro exhibit a less contractile 
phenotype after isolation from the aorta (Figure 12)33. Smooth muscle myosin heavy chain, 
MYH11, decreased by 33-fold (Figure 13B), smooth muscle actin, ACTA2, decreased by 
3-fold (Figure 13C), and myocardin, MYOCD, decreased by ~20-fold (Figure 13D) in 
the VSMCs in comparison to the aorta. Interestingly, the decrease in contractile markers 
was accompanied by a dramatic decrease in Bcl11b mRNA levels (Figure 13A).   
  
 
 
 
 
 
 
Figure 12: VSMCs in vitro are more proliferative than VSMCs in the aorta. In the 
aorta VSMCs express a quiescent and contractile phenotype while in vitro VSMC become 
proliferative, after isolation from the aorta and placed in culture. 
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Figure 13: Bcl11b mRNA expression parallels VSM contractile markers expression. 
Bcl11b (A), MYH11 (B), ACTA2 (C) and MYOCD (D) mRNA decreased in VSMCs 
compared to the aorta 
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Quiescent VSM cells express higher Bcl11b and contractile markers than 
proliferative VSM cells 
 
 To further examine a correlation between Bcl1b and VSM contractile phenotype, 
VSMCs were cultured for 72 hrs in the absence of FBS, a treatment known to revert VSM 
cells to a more quiescent and contractile phenotype similar to the VSM phenotype they 
have in the aorta in vivo. Quiescent VSMC were compared to proliferating VSM cells, 
grown in the presence of 10%FBS, in which the contractile phenotype is suppressed. 
Analysis of mRNA levels of the contractile markers showed a ~2-3-fold increase in 
MYH11, ACTA2 and MYOCD in VSMCs treated without FBS in comparison to VSMCs 
treated with FBS. Correspondingly, the levels of Bcl11b increased by ~6-fold in VSMCs 
treated without FBS compared to those treated with FBS (Figure 14). To confirm the 
change of VSMCs to a less proliferative phenotype in the absence of FBS, mRNA levels 
of cell proliferation marker Ki67 was also examined (Figure 14). As expected, there was a 
decrease in the levels of Ki67 in absence of FBS. Measurements of collagen-3 mRNA 
indicated an increase in cells treated without FBS (Figure 14), confirming that VSMCs 
acquired a phenotype similar to the one they have in the aorta in vivo, as VSMCs are a 
major source of collagen in the ECM of the aortic wall. 
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Figure 14: Bcl11b and contractile marker expressions in quiescent VSMCs versus 
proliferative VSMCs. mRNA expressions of Bcl11b and contractile markers MYH11, 
ACTA2, and MYOC, and collagen-3 in cells treated without FBS (contractile/quiescent) 
showed a significant increase compared to cells cultured in presence of FBS (proliferative). 
Cell proliferation marker Ki67 is decreased in cells treated without FBS. n=4. *, p < 0.05. 
 
 
Generation of Bcl11b specific and tamoxifen-inducible deletion in vascular smooth 
muscle 
To directly study the role of Bcl11b in VSM contractile phenotype and AS, Bcl11b 
was specifically deleted in VSM after tamoxifen administration into mice with floxed 
Bcl11b and VSM-specific (MYH11) estrogen receptor/Cre-recombinase construct. We 
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confirmed Bcl11b VSM-specific deletion by Western blot of aortic homogenates from WT 
and BKO mice, after removal of adventitia (Figure 15).  
 
Figure 15: Western blot of Bcl11b expression in aortas of WT and BKO mice. Mice 
with VSM-specific Bcl11b deletion showed absence of Bcl11b protein in aortic 
homogenates compared to WT mice (Bcl11b molecular weight is ~120kDa), as measured 
by Western blot. GAPDH used as loading control. 
 
 
Lack of Bcl11b decreases contractile markers in VSMCs. 
 To determine a cause-and-effect relationship between Bcl11b and VSM contractile 
phenotype, VSMCs isolated from aortas of WT and BKO mice were cultured with and 
without FBS for 72 hours, to measure the expression of contractile markers in proliferative 
and quiescent states, respectively. mRNA levels of MYH11, ACTA2, MYOCD and Ki67 
were measured after 72 hours. Compared to WT cells treated with FBS-containing 
medium, WT cells treated without FBS had higher levels of MYH11 (~5-fold), ACTA2 
(~2.5-fold) and MYOCD (~2-fold), and a ~2-fold decrease in levels of Ki67 (Figure 16), 
in accordance with previous findings (Figure 14). Compared to the BKO cells with FBS-
containing medium, the BKO cells without FBS containing medium had slightly higher 
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levels of MYH11, ACTA2 and MYOCD, and lower levels of Ki67. However, when 
compared to the WT, the BKO had drastically decreased levels of MYH11, ACTA2, and 
MYOCD, both in the presence or absence of FBS.  
 
 
 
Figure 16: mRNA levels of contractile and cell proliferation marker in WT and BKO 
VSMCs. VSMC isolated from with VSM-specific Bcl11b deletion (BKO) had decreased 
contractile marker than WT cells. n=3. *, p < 0.05 FBS vs no FBS; †, WT vs BKO. 
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Lack of Bcl11b impairs VSM cell contractility in vitro 
 To determine whether decreased contractile protein expression in BKO VSM cells 
had functional consequences, WT and BKO VSM cells were mixed with collagen, allowed 
to polymerize into a gel and treated with angiotensin II (angII, 100nM) or vehicle to 
measure VSM cell contractility in vitro. WT cell-containing gel showed (~50%) of 
contraction in response to 21 hours angII treatment, compared to baseline (Figure 17). BKO 
cell-containing gel showed minimal contraction in response to angII compared to its 
baseline. These results indicate that lack of Bcl11b in VSM impairs VSMC contractility. 
 
 
Figure 17: VSM cell contractility in vitro in WT and BKO cells. BKO VSMCs showed 
an impaired ability to contract under stimulation with angiotensin II compared to WT 
VSMCs. Results were plotted as a percent of baseline area. n=4. *p≤0.05 compared to 
vehicle. +p≤0.05 BKO vs WT. 
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DISCUSSION 
 
 Arterial stiffness, the loss of elasticity of large arteries, is an independent risk factor 
for cardiovascular diseases. The genetic and molecular mechanisms behind AS have not 
been fully elucidated. Our studies indicate that a dysregulation of the nuclear factor Bcl11b 
can result in increased AS, as shown by decreased Bcl11b in obese and aged mice, two 
models of AS, and in increased PWV in BKO mice. Furthermore, we showed for the first 
time that Bcl11b is expressed in the vascular smooth muscle layer of the aortic wall and 
plays an important role in vascular smooth muscle contractility, by regulating the 
expression of contractile proteins smooth muscle myosin heavy chain  11 (MYH11) and 
smooth muscle -actin (SMA or gene ID ACTA2). Our results suggest that therapeutic 
pathways targeting Bcl11b can pave the way for reducing AS and associated cardiovascular 
complications, by maintaining a functional contractile aortic wall.  
 In our study we discovered a link between Bcl11b and the contractility mechanisms 
within vascular smooth muscle. In obese mice, a model of AS, in which Bcl11b is 
decreased compared to control mice, we observed significant phenotypic alterations in 
VSM cells (Figure 11). VSMCs in aortas of obese mice had decreased expression of the 
VSMC contractile marker, MYH11, compared to ND-fed mice. MYH11 decreases were 
accompanied with increases in aortic media thickness suggesting that VSMCs acquire a 
less contractile and more proliferative phenotype, contributing to the increased thickness 
of the aortic media layer. Alterations in VSM phenotype in aortas of obese mice was further 
confirmed by increased production of inflammatory markers by these cells. Overall, these 
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results indicate that VMSCs change into a more proliferative/inflammatory and less 
contractile phenotype in settings of obesity-induced AS.  
Similarly to AS, VSMC phenotypic changes occur in several vascular diseases, 
such as atherosclerosis and aortic aneurysms27,34, and are similarly associated with 
activation of inflammatory pathways and vessel remodeling. At the molecular level, 
phenotypic modulation of VSMCs consists mainly of a decrease in VSMC contractility 
markers, such as ACTA2 and MYH1135. Under normal conditions, VSMCs exist in a non-
proliferating, quiescent, contractile state but in response to vascular injury, they have the 
ability to change into a less contractile and more proliferative state33,36. However, the 
genetic and molecular mechanisms that mediate this phenotypic switch are not fully 
elucidated. Based on a human study indicating that the genetic locus downstream of Bcl11b 
is associated with increased AS, in our study we sought to determine whether Bcl11b may 
regulate changes in VSM contractile markers in the aorta and VSM cells.  
VSM cells grown in vitro become more proliferative and less contractile compared 
to the in vivo condition, i.e. within the aorta33, as indicated by reduced mRNA and protein 
levels of ACTA2 and MYH1134,37–39. In our study, mRNA levels of VSMC differentiation 
markers decreased significantly in cultured VSMCs compared to the levels in the aorta 
(Figure 13), as expected. Interestingly we found that these changes were associated with 
decreased Bcl11b (Figure 13). Furthermore, when VSMC were cultured in absence of FBS, 
a treatment known to revert them to a more quiescent and contractile phenotype, we found 
an increase in MYH11 and ACTA2 as expected, but also an increase in Bcl11b levels 
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(Figure 14).  Therefore, our data shows for the first time a correlation between VSM 
contractile phenotype and Bcl11b.  
In addition, we demonstrated a direct link between Bcl11b and contractility genes 
by using mice with VSM-specific, tamoxifen-inducible Bcl11b deletion (Figure 15). Lack 
of Bcl11b in VSMC resulted in remarkable decreases in MYH11 and ACTA2 when 
compared to WT (Figure 16), emphasizing a cause and effect relationship between Bcl11b 
and these VSM differentiation markers. Importantly, a decrease in contractile markers in 
Bcl11b-deleted cells resulted in impairment in VSMC contractility in response to 
angiotensin II. Consistent with the fact that BKO mice had increased AS (Figure 6), our 
results strongly suggest that Bcl11b may regulate AS by regulating the expression of VSM 
contractile markers and VSMC contractility.   
Bcl11b is a cysteine2-histidine2-type (Cys2His2-type) zinc finger transcription 
factor. Zinc finger (ZnF) transcription factors are the most abundant group of transcription 
factors 40 and have functional domains coordinated by at least one zinc ion41. The Cys2His2 
domain within ZnF transcription factors stabilizes a zinc ion between two cysteine residues, 
located on a beta-sheet hairpin, and two histidine residues on an alpha-helical structure 
(Figure 18), together forming the structural finger element42. Variable amino acids near the 
alpha helix interact with bases in the major groove of DNA molecules allowing for 
sequence-specific recognition of DNA43. As a result, ZnF transcription factors can directly 
bind DNA, allowing for the regulation of downstream target genes. The Cys2His2 residues 
remain conserved between several ZnF protein families, including Bcl11b.  
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Figure 18: Example of a zinc finger motif. The Cs represent cysteine residues and the Hs 
represent histidine residues42 (Reproduced from Lee et al., Science, 1989).  
 
Bcl11b is also known as chicken ovalbumin upstream promoter transcription factor 
(COUP-TF)-interacting protein 2 (CTIP2) and functions as a transcriptional repressor in 
the brain and in the immune system44. Suzuki et al. demonstrated that CTIP2/Bcl11b binds 
to a G/C-rich sequence45, many of which are found at the transcriptional initiation in gene 
promoters without the TATA box sequence46.  
Notably, G/C-rich repressor regions are present in the gene promoter of SM22 alpha 
(transgelin), a vascular smooth muscle marker, and MYH11 between cis-activating CArG 
elements47–49. CArG boxes, also known as serum response element (SRE), correspond to 
the consensus sequence CC(AT)6GG
34,50–53. CArG elements bind serum response factors 
(SRF) which regulate MYH11 and ACTA2 expression50. In coordination with SRF, 
another transcription factor, myocardin (MYOCD), acts as a co-activator with SRF to 
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regulate ACTA2 expression54–56. As Bcl11b is known to regulate transcription in T-cells 
by binding to G/C-rich sequences, we postulated that Bcl11b may play a role in regulating 
VSMC contractile markers by binding to G/C rich elements found in the VSM gene 
promoters, thereby regulating the transcriptional activities of those contractile proteins by 
repressing a repressor element. Our data indicating that Bcl11b deletion in VSM results in 
decreased expression of VSM contractile markers (Figure 16) and impaired contractility 
after stimulation with angiotensin II, a potent vasoconstrictor (Figure 17), support our 
hypothesis. 
It is also reasonable to speculate that Bcl11b may act as a modulator of VSM 
contractile proteins by indirectly affecting the binding of transcription factors (MYOCD, 
SRF) to CArG elements within the promoter regions of MYH11 and SM22-α in the vicinity 
of Bcl11b-binding G/C cassettes. Further studies using a chromatin immunoprecipitation 
(ChIP) assay are ongoing to determine whether Bcl11b directly binds to VSM gene 
promoters. This will help us to determine whether Bcl11b modulates vascular 
differentiation markers directly rather than indirectly, via intermediary signaling pathways. 
Under normal conditions, VSMCs arrange themselves in an orderly cohesive 
network which allows for coordinated contraction and relaxation of the vasculature. A 
decrease in VSM contractile markers can result in a disorganized network between cells 
and cell-ECM interactions which may result in impaired arterial wall mechanics. 
Consequently, a dysregulation of Bcl11b can result in a dysregulation in VSM contractile 
markers which may lead to an impairment of VSM function in the aortic wall, thereby 
impairing arterial compliance. 
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 Throughout our study, we spent time optimizing the gel contractility assay as well 
as optimizing the protocol for RNA extractions. We were able to delineate a cause-and-
effect relationship between Bcl11b and the contractility apparatus of VSMCs. Currently, 
we are working with WT and BKO mice to examine whether the effects of Bcl11b deletion 
observed in VSMCs occur in the aorta thus giving us insight on molecular mechanisms in 
vivo. Furthermore, we are examining the effect of different contractile stimuli, such as 
platelet-derived-growth-factor (PDGF) or potassium chloride (KCl), to determine whether 
an impairment in Bcl11b results in damage to VSM contractility apparatus in a stimulus-
dependent fashion.  
Since a major contributing mechanism to arterial compliance is the VSMC 
organization into a regular and coordinated network, we are also examining the effect of 
protein cytoskeletal organization within VSMCs and AS. Future studies will examine 
whether Bcl11b, by regulating VSM contractile proteins, affects focal adhesion molecules 
involved in linking the VSM contractile and cytoskeletal proteins to the cell membrane and 
ECM. Recent studies have highlighted that an impairment in the focal adhesion molecules 
results in an increase in vascular stiffness in aging mice28. A disruption in both contractile 
and cytoskeletal factors can lead to improper organization of VSMCs which results in 
impaired contractility and loss of arterial compliance.  
It is also important to note that we have yet to determine the effect of 
overexpressing Bcl11b on downstream targets and whether this contributes to ameliorating 
AS in obese or aged mice by sustaining the normal function of the aortic wall.  
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 Overall, my studies contributed to elucidating genetic and molecular mechanisms 
of vascular smooth muscle contractility. A downregulation of Bcl11b was associated with 
increased AS possibly via downregulation of critical vascular smooth muscle contractile 
proteins. These findings may aid in the discovery of therapeutic targets which can restore 
the proper contractile mechanisms of the aorta to ameliorate vascular stiffness. A decrease 
in arterial stiffness can translate in effective prevention of cardiovascular events in obese 
and aging populations.  
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Biology 
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